Skip to main content
CTIS.
EU
Conditions
IMPs
Countries
Sponsors
Sites
Trial Map
Safety
Transparency
Landscape
EN — English
BG — Български
CS — Čeština
DA — Dansk
DE — Deutsch
EL — Ελληνικά
ES — Español
ET — Eesti
FI — Suomi
FR — Français
GA — Gaeilge
HR — Hrvatski
HU — Magyar
IT — Italiano
LT — Lietuvių
LV — Latviešu
MT — Malti
NL — Nederlands
PL — Polski
PT — Português
RO — Română
SK — Slovenčina
SL — Slovenščina
SV — Svenska
NO — Norsk
CTIS.
EU
✕
Conditions
IMPs
Countries
Sponsors
Sites
Trial Map
Safety
Transparency
Landscape
Notice
This is an independent non-profit initiative. We are not affiliated with the European Medicines Agency (EMA) or the official CTIS system. For the official EU Clinical Trials Information System, visit:
EMA Registry →
CTIS.eu
›
Conditions
› systemic lupus erythematosus [SLE]/lupus nephritis [LN], idiopathic inflammatory myopathy [IIM], and diffuse cutaneous systemic sclerosis [DcSSc]
systemic lupus erythematosus [SLE]/lupus nephritis [LN], idiopathic inflammatory myopathy [IIM], and diffuse cutaneous systemic sclerosis [DcSSc]
1 total trials
Filter these 1 trials by phase, country, sponsor and more.
Open in Search →
The CALiPSO-1 Study: A Study of CNTY-101, a CD19-targeted CAR iNK Cell Product, in Participants with Refractory B cell-mediated Autoimmune D …
Ended
2024-518797-13-00
3
2025-07-10
Showing 1–1 of 1 trials